The identification of unique cell surface antigens in CML has been a major challenge, but it is critically important to refine the enumeration of remaining CML LSCs within the CD34+/CD38−/Lin− fraction, as well as explore their therapeutic targeting. This evidence concerns the gene CD53 and chronic myelogenous leukemia, BCR-ABL1 positive.